文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗用于晚期黑色素瘤进展后继续治疗:两项3期临床试验分析

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
PubMed 文献 · JAMA Oncol · 2017-01-01

该研究汇总分析了两项3期临床试验中初治晚期黑色素瘤患者的数据,评估纳武利尤单抗单药在RECIST v1.1定义进展后继续治疗的安全性和潜在获益。526例随机患者中306例(58%)出现疾病进展,其中85例(28%)为进展后继续治疗组。进展后继续治疗组中24例(28%)在进展后靶病灶较基线缩小超过30%,且3-4级治疗相关不良事件与未继续治疗组相似。

要点

  • 526例患者中306例(58%)出现进展,85例(28%)为进展后继续治疗组。
  • 进展后继续治疗组中24例(28%)靶病灶较基线缩小超过30%。
  • 进展后继续治疗组与未继续治疗组3-4级治疗相关不良事件相似(5例[6%] vs 9例[4%])。

核心结论

  • 经研究者判断临床稳定且适合在RECIST v1.1定义进展后继续治疗的初治纳武利尤单抗患者中,相当比例获得明显临床获益且未影响安全性。
  • 进一步分析将有助于明确进展后继续纳武利尤单抗治疗的潜在获益。

研究设计与样本

  • 汇总回顾性分析两项3期临床试验(CheckMate 066或CheckMate 067)中初治晚期黑色素瘤患者的数据。
  • 共纳入526例随机患者(39%[n=203]为女性;中位年龄62岁[范围18-90岁])。
  • 进展后继续治疗组定义为末次纳武利尤单抗给药在进展后超过6周;未继续治疗组为在进展前或进展时停止纳武利尤单抗治疗。
  • 数据分析时间为2015年11月6日至2017年1月11日。

主要发现

  • 526例患者中306例(58%)出现疾病进展,其中85例(28%)为进展后继续治疗组,221例(72%)为未继续治疗组。
  • 进展后继续治疗组中24例(28%)在进展后靶病灶较基线缩小超过30%(即TBP>30%组)。
  • 分析时,进展后继续治疗组65例(76%)存活,TBP>30%组21例(87%)存活;分别有27例(32%)和11例(46%)继续接受治疗。
  • 进展至末次治疗的中位时间(范围):进展后继续治疗组4.7(1.4-25.8)个月,TBP>30%组7.6(2.4-19.4)个月。
  • 进展至肿瘤缩小超过30%的中位时间(范围)为1.4(0.2-7.0)个月。

临床怎么用

  • 纳武利尤单抗(3 mg/kg,每2周一次)给药至进展或不可接受毒性。
  • 若患者获得明显临床获益且耐受研究药物,研究者可酌情决定在进展后继续治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint inhibitors have demonstrated atypical response patterns, which may not be fully captured by conventional response criteria. There is a need to better understand the potential benefit of continued immune checkpoint inhibition beyond progression. OBJECTIVE: To evaluate the safety and potential benefit of nivolumab (anti-programmed cell death receptor 1) monotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST) v1.1-defined progression. DESIGN, SETTING, AND PARTICIPANTS: Pooled, retrospective analysis of data from phase 3 trials of nivolumab in treatment-naive patients with advanced melanoma (CheckMate 066 or CheckMate 067) conducted at academic and clinical cancer centers. Participants were patients treated beyond first disease progression, defined as those who received their last dose of nivolumab more than 6 weeks after progression (TBP group); and patients not treated beyond progression, who discontinued nivolumab therapy before or at progression (non-TBP group). Data analyses were conducted from November 6, 2015, to January 11, 2017. INTERVENTIONS: Nivolumab (3 mg/kg every 2 weeks) administered until progression or unacceptable toxic effects. Patients could be treated beyond progression if deriving apparent clinical benefit and tolerating study drug, at the investigator's discretion. MAIN OUTCOMES AND MEASURES: Tumor response and safety in TBP and non-TBP patients. RESULTS: Among 526 randomized patients (39% [n = 203] female; median age, 62 years [range, 18-90 years]), 306 (58%) experienced disease progression, including 85 (28%) TBP patients and 221 (72%) non-TBP patients. Twenty-four (28%) of the TBP patients had a target lesion reduction of greater than 30% after progression compared with baseline (TBP>30% group). At the time of this analysis, 65 (76%) TBP patients and 21 (87%) TBP>30% patients were still alive; 27 (32%) and 11 (46%), respectively, continued to receive treatment. Median (range) time from progression to last dose of treatment was 4.7 (1.4-25.8) months for TBP patients and 7.6 (2.4-19.4) months for TBP>30% patients. Median (range) time from progression to greater than 30% tumor reduction was 1.4 (0.2-7.0) months. Treatment-related select grade 3 to 4 adverse events were similar in the TBP and non-TBP groups (5 [6%] and 9 [4%], respectively). CONCLUSIONS AND RELEVANCE: A substantial proportion of selected patients treated with frontline nivolumab who were clinically stable and judged to be eligible for treatment beyond RECIST v1.1-defined progression by the treating investigators derived apparent clinical benefit without compromising safety. Further analysis will help define the potential benefit of continued nivolumab treatment beyond progression. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT01721772 (CheckMate 066) and NCT01844505 (CheckMate 067).

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Weber JS, Larkin J, et al. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncol. 2017. PMID: 28662232. doi:10.1001/jamaoncol.2017.1588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。